The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | MAHOGANY: margetuximab in gastric cancer
Daniel Catenacci, MD, University of Chicago, Chicago, IL, discusses the ongoing MAHOGANY study, (NCT02318329) evaluating the use of margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) with or without chemotherapy in first-line therapy of advanced, metastatic HER2 positive gastroesophageal junction or gastric cancer. Margetuximab is an investigation anti-HER2 monoclonal antibody and targets HER2 with a higher affinity than trastuzumab and has demonstrated the ability to mediate both innate and adaptive immune responses. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
